In contrast, patients with EGFR‐mutant non‐small cell lung cancer did not respond well to anti‐PD‐1/PD‐L1 immunotherapy6; however, the underlying reasons for poor responses currently remain unclear. The gene discussed is EGFR; the disease is lung cancer.